MetaVia's Dual-Action Obesity Drug Hits Key Milestone Ahead of Q4 Data

CAMBRIDGE, Mass. – August 06, 2026 – Clinical-stage biotechnology company MetaVia Inc. today announced significant progress in its ambitious clinical programs, highlighted by a critical milestone for its next-generation obesity drug, DA-1726. According to its second-quarter update, all patients in the current Phase 1 study have successfully reached the highest planned doses, setting the stage for a highly anticipated data readout in the fourth quarter of 2026 that could position the drug as a formidable new entry in the multi-billion-dollar weight-loss market.

The company is advancing a two-pronged strategy targeting major cardiometabolic diseases, with DA-1726 for obesity and a second candidate, vanoglipel, being developed as a combination therapy for liver disease and diabetes. The recent update underscores a period of intense execution for the firm, which is investing heavily in research and development to push its novel candidates forward.

"During the second quarter of 2026, and subsequently, we continued to execute across both of our clinical development programs while further strengthening the differentiated profile of DA-1726," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. He noted that the successful dose escalation represents an "important execution milestone" as the company prepares for its 16-week topline data.

A New Contender in the Crowded Obesity Market

The main focus of investor and clinical attention is DA-1726, a novel oxyntomodulin (OXM) analogue. Unlike market-leading GLP-1 agonists like semaglutide (Wegovy, Ozempic) that primarily work by suppressing appetite, DA-1726 is a dual-receptor agonist, targeting both the GLP-1 and glucagon receptors. This dual mechanism is designed not only to decrease food intake but also to increase energy expenditure, a combination that could potentially lead to more significant and sustainable weight loss.

This approach places it in the next wave of metabolic therapies, following the success of dual-action drugs like tirzepatide (Zepbound, Mounjaro), which targets GLP-1 and GIP receptors. MetaVia’s candidate aims to prove that the GLP-1/glucagon combination is a superior pathway.

Early data has been highly encouraging. Results from a previous Phase 1 trial, presented at major scientific conferences including the American Diabetes Association (ADA) and EASL Congress, showed that an earlier 48 mg dose of DA-1726 led to a mean weight loss of up to 9.1% in just eight weeks. Crucially, the weight loss trajectory showed no signs of plateauing at that point, suggesting further benefits with longer treatment. The study also reported meaningful reductions in waist circumference and positive changes in liver-related biomarkers, hinting at broader cardiometabolic benefits.

The latest milestone, announced in July, confirmed that all active patients in its ongoing 16-week Phase 1 Part 3 study successfully tolerated titration to the highest planned doses of 48 mg and 64 mg. This is a vital de-risking event, as the gastrointestinal side effects common to this class of drugs can often limit dosing. The study's design, which employs one-step and two-step titration regimens, was implemented specifically to optimize tolerability and safely reach these higher, more potent doses.

With this achievement, all eyes are now on the fourth quarter of 2026, when MetaVia expects to release 16-week topline data from this study. Strong results demonstrating continued, non-plateauing weight loss and a clean safety profile at higher doses would be a major validation of the drug’s potential and could significantly elevate its profile against established competitors.

A Strategic Play in Liver and Metabolic Disease

While DA-1726 captures the spotlight, MetaVia is concurrently advancing vanoglipel (DA-1241), a potential first-in-class drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH), the severe form of fatty liver disease. Instead of competing head-on in a complex field, the company is pursuing a savvy combination-therapy strategy.

Vanoglipel is a GPR119 agonist, a novel mechanism that stimulates the release of key gut hormones like GLP-1 and has shown direct anti-fibrotic and anti-inflammatory effects in the liver in preclinical models. Recognizing the multifactorial nature of MASH, MetaVia is positioning vanoglipel not as a standalone cure but as a complementary therapy designed to enhance the effects of other treatments.

Recent preclinical data presented at the ADA 2026 Scientific Sessions demonstrated synergistic effects when vanoglipel was combined with resmetirom—the first and only FDA-approved medication for MASH—as well as with metformin, the foundational treatment for type 2 diabetes. This suggests vanoglipel could become a valuable backbone therapy, improving outcomes for patients on existing or emerging treatments by addressing different pathological pathways. The company is now working to schedule an End-of-Phase 2 meeting with the FDA in the second half of 2026 to discuss the clinical path forward for this combination approach.

The Financial Realities of Biotech Innovation

This clinical progress comes at a cost, as reflected in MetaVia's second-quarter financial results. The company reported a net loss of $5.3 million for the quarter, up from $4.0 million in the same period last year. The increase was driven primarily by a jump in Research and Development (R&D) expenses, which rose to $3.5 million from $2.3 million year-over-year, with the bulk of the investment directed toward the DA-1726 program.

This heightened spending is typical for a clinical-stage biotech company approaching a pivotal data readout. The firm ended the quarter with $12.6 million in cash and cash equivalents. Based on its current operating expenses of approximately $5.4 million for the quarter, the company's cash runway appears sufficient to fund operations through the end of 2026, aligning with its public statements.

However, the financial runway is tight, placing immense pressure on the upcoming Q4 data. A positive outcome for DA-1726 would not only validate its scientific premise but also be critical for securing future funding to advance into more expensive later-stage trials. The company has already been actively managing its finances, recently executing a reverse stock split to maintain its Nasdaq listing and utilizing an at-the-market (ATM) equity program to raise capital. For MetaVia, the path forward hinges on converting this clinical momentum into a compelling data package that can secure both its regulatory and financial future.